Inclusion criteria
(1) All patients had an established radiological diagnosis of
bronchiectasis (HRCT of the chest); (2) patients had clinically
significant bronchiectasis expectorating mucopurulent
or purulent sputum when clinically stable; (3) clinically
stable disease with no requirement of antibiotics in the
4 weeks prior to commencing the study; (4) exercise
capacity reduced to disease process; (5) all practicing chest
clearance regularly (>4times/week) prior to study entry.